This is a multi-center, double-blind, placebo controlled clinical trial of two dosages of
oral pioglitazone (15 milligram(mg) and 45 milligram (mg)) for safety, tolerability, and
futility.
Subjects who are on stable dose of rasagiline 1 mg/day or selegiline 10 mg/day for at least 8
weeks but no more than 8 months, will be randomized to one of two dosages of oral
pioglitazone (15 mg and 45 mg) or matching placebo.
The study will measure disease progression by the change in total Unified Parkinson's Disease
Rating Scale (UPDRS) score between the baseline visit and 44 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
University of Rochester
Collaborators:
Michael J. Fox Foundation for Parkinson's Research National Institute of Neurological Disorders and Stroke (NINDS)